On May 27, 2024 Oncopeptides, a biotech company focused on difficult-to-treat cancers, reported that the first Spanish hospital will begin treating patients with Pepaxti (Press release, Oncopeptides, MAY 27, 2024, View Source [SID1234646793]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first order of the drug from a Spanish hospital follows the availability of Pepaxti in the Spanish healthcare system ("Nomenclator"), making it possible for healthcare providers to in certain cases order the product before regional access has been negotiated.

"The reception of this innovation in the medical community is a testament to the unmet medical need that this drug fills," says Sofia Heigis, CEO of Oncopeptides. "We look forward to more patients and professionals both in Spain and the rest of Europe benefitting from the clinical and quality of life results demonstrated by this treatment."

In total, 16 Spanish hospitals and more than 100 patients have participated in the clinical trials that have led to the approval of the first drug in the peptide conjugate class for the treatment of relapsed, refractory multiple myeloma.

For more information, including questions and answers for investors, please visit Oncopeptides’ website.